文献速递流行病学与生物统计真实世界研究与卫生经济

维生素和矿物质补充剂用于心血管疾病和癌症一级预防:美国预防服务工作组更新版证据报告和系统综述

Vitamin and Mineral Supplements for the Primary Prevention of Cardiovascular Disease and Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2022-01-01

该系统综述纳入84项研究(N=739 803),评估健康成人使用维生素和矿物质补充剂预防心血管疾病和癌症的获益与危害。多种维生素与任何癌症发生率降低相关(OR 0.93),β-胡萝卜素与肺癌风险(OR 1.20)和心血管死亡风险(OR 1.10)增加相关,维生素D和E与主要结局无显著关联。

要点

  • 多种维生素与任何癌症发生率降低相关(OR 0.93),但证据有重要局限性。
  • β-胡萝卜素与肺癌风险增加(OR 1.20)和心血管死亡风险增加(OR 1.10)相关。
  • 维生素D和维生素E与全因死亡、心血管疾病或癌症结局无显著关联。

核心结论

  • 维生素和矿物质补充剂在预防癌症、心血管疾病和死亡方面获益很小或没有获益,多种维生素使用对癌症发生率有小幅获益除外。
  • β-胡萝卜素与肺癌高风险人群的肺癌风险增加和其他有害结局相关。

研究设计与样本

  • 系统综述纳入84项研究(N=739 803),包括维生素或矿物质使用的随机临床试验和观察性队列研究。
  • 检索MEDLINE、PubMed、Cochrane Library和Embase(2013年1月至2022年2月1日)及既往综述。
  • 纳入标准为无心血管疾病或癌症且无已知维生素或矿物质缺乏的成人英文随机临床试验,以及检查严重危害的观察性队列研究。

主要发现

  • 多种维生素使用与任何癌症发生率降低显著相关(OR 0.93 [95% CI, 0.87-0.99];4项RCT [n=48 859];充分把握度试验中ARD范围-0.2%至-1.2%)和肺癌发生率降低相关(OR 0.75 [95% CI, 0.58-0.95];2项RCT [n=36 052];ARD 0.2%)。
  • β-胡萝卜素(伴或不伴维生素A)与肺癌风险增加显著相关(OR 1.20 [95% CI, 1.01-1.42];4项RCT [n=94 830];ARD范围-0.1%至0.6%)和心血管死亡风险增加相关(OR 1.10 [95% CI, 1.02-1.19];5项RCT [n=94 506];ARD范围-0.8%至0.8%)。
  • 维生素D使用与全因死亡(OR 0.96 [95% CI, 0.91-1.02];27项RCT [n=117 082])、复合心血管疾病事件结局(OR 1.00 [95% CI, 0.95-1.05];7项RCT [n=74 925])或任何癌症发生率(OR 0.98 [95% CI, 0.92-1.03];19项RCT [n=86 899])无显著关联。
  • 维生素E与全因死亡(OR 1.02 [95% CI, 0.97-1.07];9项RCT [n=107 772])、心血管疾病事件(OR 0.96 [95% CI, 0.90-1.04];4项RCT [n=62 136])或癌症发生率(OR 1.02 [95% CI, 0.98-1.08];5项RCT [n=76 777])无显著关联。
  • 有限证据提示某些补充剂可能与严重危害风险较高相关:髋部骨折(维生素A)、出血性卒中(维生素E)和肾结石(维生素C、钙)。

关键数值与推荐

  • 多种维生素与任何癌症发生率:OR 0.93(95% CI, 0.87-0.99),4项RCT,n=48 859。
  • β-胡萝卜素与肺癌风险:OR 1.20(95% CI, 1.01-1.42),4项RCT,n=94 830。
  • β-胡萝卜素与心血管死亡:OR 1.10(95% CI, 1.02-1.19),5项RCT,n=94 506。
  • 维生素D与全因死亡:OR 0.96(95% CI, 0.91-1.02),27项RCT,n=117 082。
  • 维生素E与全因死亡:OR 1.02(95% CI, 0.97-1.07),9项RCT,n=107 772。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 多种维生素的证据有重要局限性(原文未具体说明)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cardiovascular disease and cancer are the 2 leading causes of death in the US, and vitamin and mineral supplementation has been proposed to help prevent these conditions. OBJECTIVE: To review the benefits and harms of vitamin and mineral supplementation in healthy adults to prevent cardiovascular disease and cancer to inform the US Preventive Services Task Force. DATA SOURCES: MEDLINE, PubMed (publisher-supplied records only), Cochrane Library, and Embase (January 2013 to February 1, 2022); prior reviews. STUDY SELECTION: English-language randomized clinical trials (RCTs) of vitamin or mineral use among adults without cardiovascular disease or cancer and with no known vitamin or mineral deficiencies; observational cohort studies examining serious harms. DATA EXTRACTION AND SYNTHESIS: Single extraction, verified by a second reviewer. Quantitative pooling methods appropriate for rare events were used for most analyses. MAIN OUTCOMES AND MEASURES: Mortality, cardiovascular disease events, cancer incidence, serious harms. RESULTS: Eighty-four studies (N=739 803) were included. In pooled analyses, multivitamin use was significantly associated with a lower incidence of any cancer (odds ratio [OR], 0.93 [95% CI, 0.87-0.99]; 4 RCTs [n=48 859]; absolute risk difference [ARD] range among adequately powered trials, -0.2% to -1.2%) and lung cancer (OR, 0.75 [95% CI, 0.58-0.95]; 2 RCTs [n=36 052]; ARD, 0.2%). However, the evidence for multivitamins had important limitations. Beta carotene (with or without vitamin A) was significantly associated with an increased risk of lung cancer (OR, 1.20 [95% CI, 1.01-1.42]; 4 RCTs [n=94 830]; ARD range, -0.1% to 0.6%) and cardiovascular mortality (OR, 1.10 [95% CI, 1.02-1.19]; 5 RCTs [n=94 506] ARD range, -0.8% to 0.8%). Vitamin D use was not significantly associated with all-cause mortality (OR, 0.96 [95% CI, 0.91-1.02]; 27 RCTs [n=117 082]), cardiovascular disease (eg, composite cardiovascular disease event outcome: OR, 1.00 [95% CI, 0.95-1.05]; 7 RCTs [n=74 925]), or cancer outcomes (eg, any cancer incidence: OR, 0.98 [95% CI, 0.92-1.03]; 19 RCTs [n=86 899]). Vitamin E was not significantly associated with all-cause mortality (OR, 1.02 [95% CI, 0.97-1.07]; 9 RCTs [n=107 772]), cardiovascular disease events (OR, 0.96 [95% CI, 0.90-1.04]; 4 RCTs [n=62 136]), or cancer incidence (OR, 1.02 [95% CI, 0.98-1.08]; 5 RCTs [n=76 777]). Evidence for benefit of other supplements was equivocal, minimal, or absent. Limited evidence suggested some supplements may be associated with higher risk of serious harms (hip fracture [vitamin A], hemorrhagic stroke [vitamin E], and kidney stones [vitamin C, calcium]). CONCLUSIONS AND RELEVANCE: Vitamin and mineral supplementation was associated with little or no benefit in preventing cancer, cardiovascular disease, and death, with the exception of a small benefit for cancer incidence with multivitamin use. Beta carotene was associated with an increased risk of lung cancer and other harmful outcomes in persons at high risk of lung cancer.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. O'Connor EA, Evans CV, Ivlev I, et al. Vitamin and Mineral Supplements for the Primary Prevention of Cardiovascular Disease and Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022. PMID: 35727272. doi:10.1001/jama.2021.15650

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。